Back to Agenda
Value and Access – How Do We Strike a Balance between Both?
Session Chair(s)
Indranil Bagchi, PHD, MSC
Global Head, Pricing & Market Access, GSK, United States
Value and Access – How Do We Strike a Balance between Both?
Learning Objective : Participants will understand the payer perspective on Managed Access Agreements for high cost therapies, using examples from the NHS in England
Speaker(s)
Evert Jan van Lente, MS
Director EU-Affairs, AOK Bundesverband (Federal Insurer), Germany
Managed Access Agreements – A New Frontier in Germany?
Edmund Jessop, DrMed
Medical adviser at NHS England, National Health Service, United Kingdom
Outcome Focussed Access Agreements: Payer Perspectives
Jan McKendrick, MSC
Senior Director, PRMA Consulting Ltd, United Kingdom
Factors Leading to Difference between Regulatory and Market Access Decisions for Drugs in Six Cancers Internationally
Have an account?